Neurocrine Biosciences (NBIX) Projected to Post Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is projected to release its earnings data after the market closes on Thursday, February 6th. Analysts expect the company to announce earnings of $1.62 per share and revenue of $629.40 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Neurocrine Biosciences Trading Up 1.5 %

Shares of NASDAQ:NBIX opened at $152.42 on Wednesday. The business has a 50-day moving average price of $137.92 and a two-hundred day moving average price of $131.51. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market capitalization of $15.43 billion, a P/E ratio of 40.86 and a beta of 0.33.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NBIX shares. Morgan Stanley lifted their target price on Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a report on Tuesday. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. UBS Group boosted their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Barclays boosted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Finally, Wedbush reissued an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $166.85.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.